Welcome!

News Feed Item

Immunovaccine Announces Financial Results for the Quarter Ended September 30, 2012

HALIFAX, NOVA SCOTIA -- (Marketwire) -- 11/16/12 -- Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a clinical stage vaccine company developing the patented DepoVax(TM) vaccine-adjuvanting platform and product candidates for cancer therapy and infectious diseases, today released its financial and operational results for the quarter ended September 30, 2012.

John Trizzino, CEO of Immunovaccine, commented,

"The success of an effective therapeutic cancer vaccine will be based on a candidate that brings the right target, the right immune enhancement technology and the right therapy to the patient. The positive results from our DPX-Survivac Phase I trial validate this strategy by triggering a cancer fighting immune response in these ovarian cancer patients." He also added, "The data reported from our work on a cocaine vaccine and our focus on malaria and RSV vaccine candidates along with the expectation that these will be in human clinical trials by 2014, reinforces the value of our DepoVax(TM) platform."

Highlights of the Third Quarter 2012 and Subsequent to Quarter End:


--  Published a detailed analysis from its Phase I clinical trial of DPX-
    0907 in the Journal of Translational Medicine. The published paper
    entitled, "First-in-Man Application of a Novel Therapeutic Cancer
    Vaccine Formulation with the Capacity to Induce Multi-functional T cell
    Responses in Ovarian, Breast and Prostate Cancer Patients," highlights
    positive data including targeted multi-functional immunotherapeutic
    responses generated by DPX-0907.

--  Scott Halperin, M.D., joined the Company's scientific advisory board
    (SAB). Dr. Halperin strengthens the SAB's broad expertise in infectious
    diseases vaccine research and development, particularly in the area of
    clinical trial design and execution.

--  Positive interim results from the Company's Phase I clinical trial of
    DPX-Survivac, an ovarian cancer vaccine candidate. The ongoing Phase I
    study is evaluating the potency, safety and tolerability of DPX-Survivac
    alone or in combination with low dose oral cyclophosphamide. Interim
    results showed that, to date, all nine patients receiving DPX-Survivac,
    in combination with cyclophosphamide, produced a targeted immune
    response following only one or two vaccine administrations.

--  Positive results from a preliminary study of an anti-cocaine vaccine in
    collaboration with Weill Cornell Medical College. The study showed that
    the vaccine, which added Immunovaccine's DepoVax(TM)-adjuvanting
    technology to Weill Cornell's novel anti-cocaine vaccine (dAd5GNE),
    produced high levels of target antibodies that were able to sequester
    cocaine in the blood of immunized mice and block its delivery to the
    brain.

Q3 2012 Financial Results

The Company prepares its unaudited interim condensed consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Handbook of the Canadian Institute of Chartered Accountants - Part I ("CICA Handbook"), which incorporates International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

The Company's net loss for the period increased from a loss of $1.5 million during the quarter ended September 30, 2011 to a loss of $1.7 million during the quarter ended September 30, 2012. This relates mainly to the $155,000 increase in general and administration expenses, a $33,000 increase in business development expenses and a $28,000 increase in research and development costs.

For the quarter ended September 30, 2012, the Company reported total R&D expenses of $1.0 million, less government loans and assistance of $191,000 and investment tax credits of $80,000. This represented a $28,000 increase over the three months ended September 30, 2011. G&A expenses of $491,000 were reported for Q3 Fiscal 2012 compared to $336,000 for the three months ended September 30, 2011, an overall increase of $155,000. Total business development expenses of $191,000 in Q3 Fiscal 2012 represented an increase of $33,000 compared to the three months ended September 30, 2011.

At September 30, 2012, Immunovaccine had cash and cash equivalents of $3.6 million and working capital of $3.7 million as compared to $5.1 million in both cash and working capital at December 31, 2011.

As of November 15, 2012, the number of issued and outstanding common shares was 63,505,152. On September 30, 2012, the number of stock options outstanding was 4,982,150 and the number of outstanding warrants was 3,732,550.

Immunovaccine's unaudited interim condensed consolidated financial statements for September 30, 2012, filed in accordance with IFRS, and the management discussion and analysis (MD&A), are available at www.sedar.com.

Amendments to its Stock Option Plan

In addition, the Board of Directors of Immunovaccine approved certain modifications to the Plan to increase the number of common shares of the Corporation reserved for issuance under the Plan from 5,300,000 to 6,250,000. The modifications to the Plan were approved by the TSX Venture Exchange on November 15, 2012.

Retains Brisco Capital Partners Corp. for Strategic Investor Relations Services

The Company is pleased to announce it has retained Brisco Capital Partners Corp ("Brisco") to provide strategic investor relations services. Brisco will aid the Company in building awareness in the financial community by introducing, maintaining and protecting relationships between the management of the Company and professional investors. Based in Calgary, Alberta, Brisco is an investor relations firm with a broad range of clients representing a cumulative market capitalization of $3.3 billion. Neither Brisco nor any of its principals have an ownership interest, directly or indirectly, in Immunovaccine.

Under the terms of the agreement with Brisco, the Company will pay Brisco a monthly fee of $7,500 and is granting Brisco 250,000 stock options under its Amended Stock Option Plan. The options are exercisable at the earlier of 24 months from the date of grant or 30 days after Brisco ceases to be engaged, at an exercise price of $0.39 per share and the options are subject to vesting over 12 months with one-quarter of the options vesting each quarter. The options follow the guidelines as set out in the Company's stock option plan and as set by TSX Venture Exchange. The consulting agreement and the options granted thereby are subject to the approval of the TSX Venture Exchange. The agreement has a term of 12 months, unless extended in writing, but may be terminated by either party with 30 days written notice.

About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax(TM) platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Immunovaccine Inc.
Kimberly Stephens
CFO
(902) 492-1819
[email protected]
www.imvaccine.com

Vida Communication (media)
Tim Brons
(415) 675-7402
[email protected]

Vida Communication (investors)
Stephanie Diaz
(415) 675-7401
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
ReadyTalk has expanded the capabilities of the FoxDen collaboration platform announced late last year to include FoxDen Connect, an in-room video collaboration experience that launches with a single touch. With FoxDen Connect, users can now not only engage in HD video conferencing between iOS and Android mobile devices or Chrome browsers, but also set up in-person meeting rooms for video interactions. A host’s mobile device automatically recognizes the presence of a meeting room via beacon tech...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
On Dice.com, the number of job postings asking for skill in Amazon Web Services increased 76 percent between June 2015 and June 2016. Salesforce.com saw its own skill mentions increase 37 percent, while DevOps and Cloud rose 35 percent and 28 percent, respectively. Even as they expand their presence in the cloud, companies are also looking for tech professionals who can manage projects, crunch data, and figure out how to make systems run more autonomously. Mentions of ‘data science’ as a skill ...
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.